Retrospective Claims Analysis of Treatment Patterns, Relapse, Utilization, and Cost Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy
Authors:
Open Access
- 16 June 2021
- journal article
- research article
- Published by Springer Nature in Drugs - Real World Outcomes
- Vol. 8 (4) , 497-508
Abstract
Background Real-world studies of disease-modifying therapies (DMTs) in multiple sclerosis (MS) have reported suboptimal adherence. Objective We aimed to describe treatment patterns, relapses, healthcare resource utilization, and costs in MS patients experiencing their first observed DMT switch. Methods In this retrospective, claims database study, adult patients were selected if they had an MS diagnosis and DMT claim during the study period (1 January 2009–31 March 2019). Patients who switched to a new DMT between 1 January 2010 and 31 March 2018 were included. Adherence, persistence, relapses, and all-cause and MS-related healthcare utilization and costs were reported pre- and post-index. Results In total, 1554 MS patients were identified; the mean age was 46 years and most (74%) were female. The majority of patients switched from an injectable DMT (n = 1116; 71.8%), and patients generally switched to an oral DMT (n = 878; 57%). Among patients who switched DMTs, 46.0% (n = 715) were nonadherent, 42% (n = 645) were nonpersistent, and 21.5% (n = 334) relapsed in the 12 months post-switch. An increase in all-cause and MS-related healthcare costs was observed pre- to post-index for all patients. Cost drivers included outpatient visit costs and pharmacy prescriptions. Compared with patients who switched to an injectable DMT, those who switched to an oral DMT had significantly higher persistence and adherence. No significant difference was observed in post-index relapse or all-cause and MS-related total cost of care. Conclusion Low adherence and poor persistence remain following an initial DMT switch; however, patients who switched to oral DMTs had higher persistence and adherence.Keywords
This publication has 27 references indexed in Scilit:
- Economic costs associated with an MS relapseMultiple Sclerosis and Related Disorders, 2014
- Incidence, Prevalence, Costs, and Impact on Disability of Common Conditions Requiring Rehabilitation in the United States: Stroke, Spinal Cord Injury, Traumatic Brain Injury, Multiple Sclerosis, Osteoarthritis, Rheumatoid Arthritis, Limb Loss, and Back PainArchives of Physical Medicine and Rehabilitation, 2014
- Multiple Sclerosis: Overview of Disease-Modifying AgentsPerspectives in Medicinal Chemistry, 2014
- Direct and indirect cost burden associated with multiple sclerosis relapses: Excess costs of persons with MS and their spouse caregiversJournal of the Neurological Sciences, 2013
- Medical chart validation of an algorithm for identifying multiple sclerosis relapse in healthcare claimsJournal of Medical Economics, 2010
- Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherencePatient Preference and Adherence, 2010
- Concepts of induction and escalation therapy in multiple sclerosisJournal of the Neurological Sciences, 2009
- Contribution of relapses to disability in multiple sclerosisJournal of Neurology, 2008
- Effect of relapses on development of residual deficit in multiple sclerosisNeurology, 2003
- Clinical and Economic Impact of Glatiramer Acetate Versus Beta Interferon Therapy Among Patients With Multiple Sclerosis in a Managed Care PopulationJournal of Managed Care Pharmacy, 2002